NCT06236061 - Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy | Biotech Hunter

Enrollment

718

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

May 28, 2025

Study Completion Date

December 25, 2025

Conditions

Hypertension

Interventions

DRUG

LCZ

LCZ 200 mg

DRUG

LCZ/AML 200 mg/2.5 mg

DRUG

LCZ/AML 200 mg/5 mg

DRUG

LCZ/AML 200 mg/10 mg

OTHER

Placebo

Matching placebo of Amlodipine.

Trial Locations (43)

451-8511

Novartis Investigative Site, Nagoya

453-0804

Novartis Investigative Site, Nagoya

454-0933

Novartis Investigative Site, Nagoya

457-8511

Novartis Investigative Site, Nagoya

819-1104

Novartis Investigative Site, Itoshima

066-0032

Novartis Investigative Site, Chitose

003-0026

Novartis Investigative Site, Sapporo

063-0826

Novartis Investigative Site, Sapporo

063-0842

Novartis Investigative Site, Sapporo

674-0081

Novartis Investigative Site, Akashi

660-0861

Novartis Investigative Site, Amagasaki

305-0861

Novartis Investigative Site, Tsukuba

247-0055

Novartis Investigative Site, Kamakura

211-0041

Novartis Investigative Site, Kawasaki-shi

231-0023

Novartis Investigative Site, Yokohama

232-0064

Novartis Investigative Site, Yokohama

989-6143

Novartis Investigative Site, Ōsaki

980-0011

Novartis Investigative Site, Sendai

983-0039

Novartis Investigative Site, Sendai

565-0853

Novartis Investigative Site, Suita

101-0041

Novartis Investigative Site, Chiyoda City

104-0031

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Chuoh-ku

103-0027

Novartis Investigative Site, Chuo-ku

192-0046

Novartis Investigative Site, Hachiōji

204-0021

Novartis Investigative Site, Kiyose

180-0022

Novartis Investigative Site, Musashino

177-0051

Novartis Investigative Site, Nerima Ku

155-0031

Novartis Investigative Site, Setagaya-ku

150-0013

Novartis Investigative Site, Shibuya City

141-0032

Novartis Investigative Site, Shinagawa-Ku

160-0008

Novartis Investigative Site, Shinjuku Ku

160-0017

Novartis Investigative Site, Shinjuku-ku

169-0072

Novartis Investigative Site, Shinjuku-ku

166-0003

Novartis Investigative Site, Suginami-ku

171-0021

Novartis Investigative Site, Toshima-Ku

810-0021

Novartis Investigative Site, Fukuoka

732-0053

Novartis Investigative Site, Hiroshima

615-8125

Novartis Investigative Site, Kyoto

530-0002

Novartis Investigative Site, Osaka

532-0003

Novartis Investigative Site, Osaka

536-0008

Novartis Investigative Site, Osaka

550-0013

Novartis Investigative Site, Osaka